Loading
Nanoparticle-based Drug Delivery / Nanoplatforms for Cancer Theranostics · Journal article
Journal of Drug Targeting · August 17, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review that synthesizes recent advances in the design and therapeutic applications of carrier-free nanoparticles across multiple cancer types and modalities (chemotherapy, photothermal, photodynamic, chemodynamic, ferroptosis, and immunotherapy). The review acknowledges insufficient systematic understanding linking nanoparticle design, tumor-specific responses, and clinical translation, and calls attention to current clinical progress and future challenges without reporting definitive efficacy or safety data.
Journal article. Cancer patients (breast, lung, and liver cancers); review covers preclinical and translational studies.
Carrier-free nanoparticles characterized by ultrahigh drug-loading capacity, reduced dependence on inert carriers, and enhanced therapeutic efficiency Assembly strategies include molecular self-assembly, covalent prodrug conjugation, and stimuli-responsive construction Therapeutic applications span breast, lung, and liver cancers with six distinct therapeutic modalities discussed
No original clinical trial data, efficacy outcomes, or safety metrics reported
This review is intended to inform the rational design and clinical development of carrier-free nanoparticles; however, it does not provide quantitative evidence of clinical efficacy or safety and is best read as a state-of-the-field summary identifying opportunities and gaps rather than as definitive guidance for clinical practice.
This is a narrative review article synthesizing preclinical and early translational work on carrier-free nanoparticles; it raises questions and organizes the field rather than reporting original clinical trial data or definitive evidence.
This review is intended to inform the rational design and clinical development of carrier-free nanoparticles; however, it does not provide quantitative evidence of clinical efficacy or safety and is best read as a state-of-the-field summary identifying opportunities and gaps rather than as definitive guidance for clinical practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Carrier-free nanoparticles have emerged as a promising class of nanomedicines for cancer therapy, characterized by ultrahigh drug-loading capacity, reduced dependence on inert carriers, and enhanced therapeutic efficiency. Diverse design strategies, including molecular self-assembly, covalent prodrug conjugation, and stimuli-responsive construction, have enabled the development of structurally versatile and functionally integrated carrier-free nanoplatforms. These systems exhibit improved physicochemical properties, enhanced tumor accumulation, and multifunctional therapeutic capabilities. However, existing reviews have mainly focused on specific assembly strategies or individual therapeutic applications, while a systematic understanding linking nanoparticle design, tumor-specific responses, and clinical translation remains insufficient. This review summarizes recent advances in the design and fabrication of carrier-free nanoparticles and provides an integrated analysis of their assembly mechanisms, physicochemical characteristics, and therapeutic applications across diverse cancer types, including breast, lung, and liver cancers. In addition, this review comparatively discusses different therapeutic modalities, including chemotherapy, photothermal therapy, photodynamic therapy, chemodynamic therapy, ferroptosis, and immunotherapy, with emphasis on their advantages, limitations, and translational potential. Current clinical progress, patent trends, and future challenges are also analyzed to provide insights into the rational design and clinical development of carrier-free nanoparticles for cancer therapy.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.